English | Español

Abbvie
Press release submission | Jul 24, 2021

DALVANCE® (dalbavancin) Receives FDA Approval to Treat Acute Bacterial Skin and Skin Structure Infections in Pediatric Patients

Press release submission | Aug 15, 2020

ABBVIE: New England Journal of Medicine Publishes Positive Phase 3 Data of Venetoclax Combination in Acute Myeloid Leukemia (AML) Patients
Press release submission | Nov 26, 2018

ABBVIE: Receives US FDA Accelerated Approval for VENCLEXTA® (venetoclax) for Treatment of Newly-Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy
Press release submission | Oct 26, 2018

ABBVIE: To Assume Full Development and Commercial Control of Cystic Fibrosis Research Program
Press release submission | Sep 23, 2018

ABBVIE: Announces $5 Million Donation to Family Reach to Support Children Battling Cancer and Their Families
Carrie Bradon | Nov 28, 2017

AbbVie to take part in Evercore ISI Biopharma Catalyst conference
Kathy Adams | Nov 15, 2017

AbbVie executive to present at Jefferies London Healthcare Conference
Robert Hadley | Nov 7, 2017

FDA fast-tracking review for AbbVie’s endometriosis drug

Trending
Patient Daily | Sep 3, 2025

Top healthcare marketing experts to present at AOCOO-HNS 2025 virtual mid-year symposium, led by Greg Caesar of Medfluence Advisors
+ Pharmaceuticals
Patient Daily | Sep 4, 2025

PhRMA CEO on 340B abuse: ‘Big hospitals are abusing the 340B program to markup medicine prices’
+ Pharmaceuticals
Patient Daily | Aug 29, 2025

Deputy VP of Public Affairs of PhRMA on 340B: ‘Over 80% of all rural hospital beds were actually in urban hospitals’
+ Pharmaceuticals
Patient Daily | Sep 2, 2025

Fmr. Gov. Dean on 340B: ‘There's no actual requirement for hospitals to pass along the savings’